硫酸镁联合拉贝洛尔治疗子痫前期患者的有效性分析

目的分析硫酸镁联合拉贝洛尔治疗子痫前期患者的有效性。方法 102例子痫前期患者,随机分为甲组和乙组,每组51例。甲组患者采用硫酸镁联合拉贝洛尔治疗,乙组患者采用硫酸镁治疗。比较两组患者治疗前后血压水平,并发症发生情况,治疗前后24 h尿蛋白含量,治疗前后血液流变等指标水平,治疗效果。结果治疗前,两组患者的舒张压和收缩压水平比较,差异无统计学意义(P>0.05);治疗后,甲组患者的舒张压(75.32±10.74)mm Hg(1 mm Hg=0.133 kPa)和收缩压(134.53±8.43)mm Hg均显著低于乙组的(88.53±10.23)、(155.75±9.75)mm Hg,差异均具有统计学意义(P<0.05)。甲组患者发生宫颈裂伤2例、子宫过度收缩3例、产后出血1例,并发症发生率为11.76%(6/51);乙组患者发生宫颈裂伤6例、子宫过度收缩5例、产后出血4例,并发症发生率为29.41%(15/51);甲组患者的并发症发生率显著低于乙组,差异具有统计学意义(P<0.05)。治疗前,两组患者的24 h尿蛋白含量比较,差异无统计学意义(P>0.05);治疗后,两组患者的24 h尿蛋白含量均低于治疗前,且甲组患者的24 h尿蛋白含量显著低于乙组,差异具有统计学意义(P<0.05)。治疗前,两组患者的全血粘度、血浆粘度、红细胞比容比较,差异无统计学意义(P>0.05);治疗后,甲组患者的全血粘度、血浆粘度、红细胞比容均显著低于乙组,差异均具有统计学意义(P<0.05)。甲组患者的治疗有效率为96.08%,显著高于乙组的84.31%,差异具有统计学意义(P<0.05)。结论硫酸镁联合拉贝洛尔治疗子痫前期患者的有效性更明显,治疗效果更高,并发症更少,血液流变学指标变化更显著, 24 h尿蛋白含量更低,血压变化更突出,是一种可行的治疗方法。

Efficacy of magnesium sulfate combined with labetalol in the treatment of preeclampsia

Objective To analyze the efficacy of magnesium sulfate combined with labetalol in the treatment of preeclampsia. Methods A total of 102 preeclampsia patients were randomly divided into group A and group B, with 51 cases in each group. Group A was treated by magnesium sulfate combined with labetalol, and group B was treated by magnesium sulfate. The blood pressure before and after treatment, occurrence of complications, 24 h urinary protein content and hemorheology index before and after treatment and therapeutic effect was compared between the two groups. Results Before treatment, there was no statistically significant difference in diastolic blood pressure and systolic blood pressure between the two groups(P>0.05). After treatment, the diastolic blood pressure(75.32±10.74) mm Hg(1 mm Hg=0.133 kPa) and systolic blood pressure(134.53±8.43) mm Hg was significantly lower than(88.53±10.23) and(155.75±9.75) mm Hg in group B, and their difference was statistically significant(P<0.05). Group A had 2 cases of cervical laceration, 3 cases of excessive uterine contraction and 1 case of postpartum hemorrhage, and the incidence of complications was 11.76%(6/51). Group B had 6 cases of cervical laceration, 5 cases of excessive uterine contraction and 4 cases of postpartum hemorrhage, and the incidence of complications was 29.41%(15/51). The incidence of complications in group A was significantly lower than that in group B, and the difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in 24 h urinary protein content between the two groups(P>0.05). After treatment, the 24 h urinary protein content in the two groups was lower than those before treatment, and the 24 h urinary protein content in group A was significantly lower than that in group B. Their difference was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in whole blood viscosity, plasma viscosity and hematocrit between the two groups(P>0.05). After treatment, the whole blood viscosity, plasma viscosity and hematocrit in group A was significantly lower than those in group B, and their difference was statistically significant(P<0.05). The effective rate of treatment was 96.08% in group A, which was significantly higher than 84.31% in group B, and the difference was statistically significant(P<0.05). Conclusion Magnesium sulfate combined with labetalol shows obvious efficacy in the treatment of preeclampsia patients, with higher therapeutic effect, fewer complications, more significant changes in hemorheology indexes, lower 24 h urinary protein content, more prominent changes in blood pressure. It is a feasible treatment.